These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 1867231)

  • 1. Regression of coronary atherosclerosis: an achievable goal? Review of results from recent clinical trials.
    Waters D; Lespérance J
    Am J Med; 1991 Jul; 91(1B):10S-17S. PubMed ID: 1867231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for treatment.
    Gotto AM
    Am J Med; 1991 Jul; 91(1B):31S-36S. PubMed ID: 1867234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of aggressive lipid management in patients at risk: evidence from recent clinical trials.
    Ferdinand KC
    Clin Cardiol; 2004 Jun; 27(6 Suppl 3):III12-5. PubMed ID: 15239486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression and regression of the atherosclerotic plaque.
    de Feyter PJ; Vos J; Deckers JW
    Eur Heart J; 1995 Aug; 16 Suppl I():26-30. PubMed ID: 8829954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study.
    Hodis HN
    J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S25-31. PubMed ID: 8907211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating lipid abnormalities in patients with type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2001 Dec; 88(12A):37N-40N. PubMed ID: 11788129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
    Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of blood lipid abnormalities in coronary heart disease patients.
    Kuo PT
    Clin Cardiol; 1989 Oct; 12(10):553-60. PubMed ID: 2680196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.
    Frick MH; Syvänne M; Nieminen MS; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Taskinen MR
    Circulation; 1997 Oct; 96(7):2137-43. PubMed ID: 9337181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future treatment of hyperlipidemia: the role of statins.
    Farnier M; Davignon J
    Am J Cardiol; 1998 Aug; 82(4B):3J-10J. PubMed ID: 9737640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Red grape seed extract improves lipid profiles and decreases oxidized low-density lipoprotein in patients with mild hyperlipidemia.
    Razavi SM; Gholamin S; Eskandari A; Mohsenian N; Ghorbanihaghjo A; Delazar A; Rashtchizadeh N; Keshtkar-Jahromi M; Argani H
    J Med Food; 2013 Mar; 16(3):255-8. PubMed ID: 23437789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
    Després JP
    Am J Cardiol; 2001 Dec; 88(12A):30N-36N. PubMed ID: 11788128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Existing and investigational combination drug therapy for high-density lipoprotein cholesterol.
    Bays H
    Am J Cardiol; 2002 Nov; 90(10B):30K-43K. PubMed ID: 12467938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).
    Blankenhorn DH; Azen SP; Kramsch DM; Mack WJ; Cashin-Hemphill L; Hodis HN; DeBoer LW; Mahrer PR; Masteller MJ; Vailas LI; Alaupovic P; Hirsch LJ;
    Ann Intern Med; 1993 Nov; 119(10):969-76. PubMed ID: 8214993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender-based mortality follow-up from the Program on the Surgical Control of the Hyperlipidemias (POSCH) and meta-analysis of lipid intervention trials. Women in POSCH and other lipid trials.
    Buchwald H; Campos CT; Boen JR; Nguyen P; Williams SE; Lau J; Chalmers TC
    Ann Surg; 1996 Oct; 224(4):486-98; discussion 498-500. PubMed ID: 8857853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
    Frisinghelli A; Mafrici A
    Clin Drug Investig; 2007; 27(9):591-604. PubMed ID: 17705568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting.
    Barbir M; Hunt BJ; Galloway D; Taylor A; Ilsley C; Mitchell A; Yacoub M
    Clin Cardiol; 1994 Feb; 17(2):59-64. PubMed ID: 8162627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and regression of coronary atherosclerosis. Is it safe and efficacious therapy?
    Montague T; Tsuyuki R; Burton J; Williams R; Dzavik V; Teo K
    Chest; 1994 Mar; 105(3):718-26. PubMed ID: 8131532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of coronary angiography on use of lipid-lowering agents in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. For the WISE Investigators.
    Bittner V; Olson M; Kelsey SF; Rogers WJ; Bairey Merz CN; Armstrong K; Reis SE; Boyette A; Sopko G
    Am J Cardiol; 2000 May; 85(9):1083-8. PubMed ID: 10781756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study.
    Nikkilä EA; Viikinkoski P; Valle M; Frick MH
    Br Med J (Clin Res Ed); 1984 Jul; 289(6439):220-3. PubMed ID: 6430414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.